ALKS

AlkermesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

22%

Probability

Target price

$61.00

+15.7% vs current

Most likely

Base case

46%

Probability

Target price

$50.00

-5.2% vs current

B-

Bear case

32%

Probability

Target price

$41.00

-22.2% vs current

AI sentiment snapshot

Latest data as of 2026-07-07

AI commentary

Headline flow over the last month was constructive and centered on alixorexton and the sleep-medicine strategy, but this remains a tentative monitoring view rather than a standard-conviction thesis. Primary-source support is solid for the disclosed data, designations and Q1 operating context, yet forward evidence is still limited, the deterministic prior is negative, and the stock is above the packet's median target. No reliable packet data was supplied for social, options, short-interest or employee sentiment, so missing sentiment channels should not be read as positive evidence.

RankAlpha Sentiment Codex - 2026-07-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-15eventOrphan-drug designations add regulatory support for alixorextonMedium impact

Alkermes disclosed via 8-K that it issued a press release announcing orphan drug designations for alixorexton in the U.S. and Europe. The designations strengthen the asset's regulatory profile, but they do not by themselves change near-term commercialization or earnings power [#8-K-2026-06-15].

2026-06-17catalystDetailed Vibrance-2 data supports alixorexton but likely adds only incremental de-riskingMedium impact

Detailed SLEEP 2026 data showed alixorexton met dual primary endpoints in narcolepsy type 2, with statistically significant improvement on wakefulness and sleepiness measures at key doses and generally good tolerability. This keeps the sleep-franchise narrative constructive, but topline success had already been disclosed, so the June update looks more incremental than thesis-resetting [#PR-EARNINGS-2026-06-17].

2026-12-31catalystAvadel integration, LUMRYZ ramp and Brilliance phase 3 execution remain the real rerating testHigh impact

Q1 2026 results showed $392.9 million of revenue, $338.1 million of proprietary net sales, initial LUMRYZ contribution after the Avadel acquisition, and initiation of the Brilliance phase 3 narcolepsy program in Q1 2026. Durable upside likely depends on clean LUMRYZ integration, commercial execution and continued phase 3 progress rather than conference data alone [#SEC-8K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-07 • Updated nightlySource: Internal modelMethodology